Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Hoth Therapeutics News

Aktie
WKN:  A3DZJ0 ISIN:  US44148G2049 US-Symbol:  HOTH Branche:  Biotechnologie Land:  USA
0,7271 $
-0,0125 $
-1,69%
0,6181 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
11,28 Mio. €
Streubesitz
87,82%
KGV
-1,23
Index-Zuordnung
-

Hoth Therapeutics News

14.04.26 - PR Newswire
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-​Creation Gene and Activates Fat-​Burning Pathways, ...
13.04.26 - PR Newswire
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-​Creation Gene and Activates Fat-​Burning Pathways, ...
02.04.26 - PR Newswire
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PR Newswire
01.04.26 - PR Newswire
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering PR Newswire
01.04.26 - PR Newswire
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six PR Newswire
31.03.26 - PR Newswire
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-​Targeting Technology PR Newswire
26.03.26 - PR Newswire
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery PR Newswire
24.03.26 - PR Newswire
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-​Associated Skin Toxicities Showing ~77% Increase in Drug ...
10.03.26 - PR Newswire
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model PR Newswire
04.03.26 - PR Newswire
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program PR Newswire
24.02.26 - PR Newswire
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES PR Newswire
12.02.26 - PR Newswire
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-​Skipping Therapy Targeting Allergic Diseases PR Newswire
10.02.26 - PR Newswire
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model ...
05.02.26 - PR Newswire
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets PR Newswire
22.01.26 - PR Newswire
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-​Label PK Cohort of EGFR-​Treated Cancer Patients PR Newswire
21.01.26 - PR Newswire
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position PR Newswire
15.01.26 - PR Newswire
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-​Country Site Activation PR Newswire
02.01.26 - PR Newswire
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform PR Newswire
03.12.25 - PR Newswire
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-​Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic ...
01.12.25 - PR Newswire
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025
Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »